Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UBY8

UPID:
CLN8_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9UBY8; Q86U71; Q96I95

BACKGROUND:
The function of Protein CLN8, with UniProt accession Q9UBY8, involves critical roles in neuronal cell proliferation and anti-apoptotic mechanisms. This protein's activity is essential for the proper development and maintenance of neural tissues.

THERAPEUTIC SIGNIFICANCE:
Linked to severe neurodegenerative diseases such as neuronal ceroid lipofuscinosis type 8 and its variant, Northern epilepsy, Protein CLN8's study offers a promising avenue for the development of novel treatments aimed at mitigating the progression of these disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Error: Google reCAPTCHA script is not loaded. Make sure your browser is not blocking it or contact the site administrator.